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Heart rate variability in overactive bladder
experimental model
Łukasz Dobrek, Piotr Thor
A b s t r a c t
Introduction: Two main pathophysiological concepts of overactive bladder (OAB)
are postulated: the neurogenic and myogenic theories. Autonomic nervous sys-
tem (ANS) dysfunction is also involved in OAB pathophysiology. The purpose of
our study was to estimate ANS activity by heart rate variability (HRV) assessment
in two OAB experimental models evoked by cyclophosphamide administration:
acute (AOAB) and chronic (COAB) overactive ones. 
Material and methods: In the AOAB model, an i.p. dose of cyclophosphamide
was administered (200 mg/kg body weight) while the COAB model received 
4 times the i.p. administration of cyclophosphamide (75 mg/kg body weight).
In each subject, after urethane anaesthesia (1.2 g/kg body weight), 20-minute
ECG recordings (PowerLab) were performed with subsequent HRV analysis. 
Results: Most of the differences in time domain analysis parameters were
insignificant, except those concerning SDNN and rMSSD (p < 0.05). In frequency
analysis, a power decrease of all standard spectral components was revealed
in both OAB groups. In AOAB, TP (1.43 ±1.21 vs. 7.92 ±6.22 in control; p < 0.05)
and VLF (0.95 ±1.08 vs. 6.97 ±5.99 in control; p < 0.05) showed significant pow-
er decrease, whereas the COAB group was mostly characterized by LF (0.09 ±0.15
vs. 0.34 ±0.33 in control; p < 0.05) and HF (0.25 ±0.29 vs. 0.60 ±0.41 in control;
p < 0.05) decrease. 
Conclusions: The ANS disturbances, found as standard spectral parameter abnor-
malities, were demonstrated in both AOAB and COAB. When this finding is ana-
lysed, together with the lack of statistically significant differences in normalized
nLF and nHF powers, the VLF changes seem to play an essential role, probably
reflecting the progression in bladder inflammatory changes.
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Introduction
The common overactive bladder (OAB) definition was given in 2002 by
the International Continence Society (ICS) as urinary urgency with or with-
out urge incontinence, usually associated with frequency and nocturia, in
the absence of proven pathological or metabolic disorders or other obvious
pathology [1]. According to a 2006 OAB update to the latest terminology,
the reviewed OAB definition is urgency with or without urgency inconti-
nence, usually with increased daytime frequency and nocturia [2]. This
clinical entity occurs with global prevalence ranging from 8% to 14%,
depending on variations in studied populations including sex, age and dif-
ferent diagnostic criteria [3]. 
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There are two main pathophysiological theories
describing OAB development – myogenic and neuro-
genic ones. The first one considers abnormal smooth
muscle myoelectrical activity as the predominant
OAB pathogenetic factor. According to neurogenic
background, it is postulated that OAB may result
from lack of central nervous inhibition of voiding or
may be secondary to afferent/efferent autonomic
fibre dysfunction [4-6]. Therefore, it is important to
estimate autonomic nervous system (ANS) func-
tioning, the altered activity of which may cause 
a predisposition to OAB. Nowadays, it is possible to
evaluate ANS activity for research purposes using
multiple tests based on the cardiovascular reflexes
as well as direct catecholamine measurements [7].
However, the best non-invasive method of ANS indi-
rect assessment is the heart rate variability (HRV)
study. The HRV is the temporary variation of R-R
intervals observed in ECG recording that is modu-
lated by autonomic influences [7-9]. Two main types
of HRV analysis may be identified: time domain [8,
10], based on the main parameter mNN [ms] and
other statistically derived values; and frequency
(spectral) domain [8, 11], estimating the power spec-
trum and its components (TP, VLF, LF, HF). 
Nevertheless, OAB is characterized by the detru-
sor overreactivity (DO) phenomenon, which is the
main abnormality noted in urodynamic studies
(bladder motility recordings). DO can be explored
using experimental OAB models. One of the best
described and methodically developed is that of
chemical cystitis induced by cyclophosphamide
(CYP). This model, first proposed by Cox [12], is fre-
quently used by other researchers in this field, often
with minor modifications.
The purpose of the study was to estimate ANS
activity by HRV analysis assessment in an animal
model of OAB. We used one of the best described
and explored OAB experimental models – haemorr-
hagic cystitis (HC) evoked by CYP. 
Material and methods
Ethics
The study protocol was approved by the First
Local Ethic Committee in Cracow (agreement deci-
sion 126/2010). 
Animals and studied groups
The experiment was carried out using 70 female
rats (Wistar). The animals were obtained from the
central laboratory. On arrival at the animal house of
the Pathophysiology Department the rats were
allowed an acclimatization period of 1 week in groups
of five per cage. The animals were housed at room
temperature, with a 12-12 h day-night cycle, with
standard food (Labofeed Kcynia) and ad libitum
water. Cyclophosphamide (CYP), a nitrogen mustard-
type chemotherapeutic agent, was injected intraperi-
toneally (i.p.) to produce a model of chemically
induced haemorrhagic cystitis (HC). According to CYP
dose and route of administration, there is a possi-
bility of inducing an ‘acute overactive bladder’ (AOAB)
model, or a chronic case (COAB) may be evoked [13,
14]. We conducted our study in both AOAB and COAB.  
Thus, three groups were studied: control rats 
(10 animals; mean body weight: 273.3 ±36.0 g) and
the AOAB (30 rats, mean body weight: 306.8 ±30.4 g)
and COAB groups (30 rats, mean body weight: 289.3
±42.1 g). 
The number of rats in all studied groups was
dependent on the entire research project; the auto-
nomic nervous system assessment by heart rate
variability was the first phase of a wider experi-
ment. The further step was urodynamic evaluation
of bladder functioning after administration of two
studied agents: melatonin and agomelatine. We
planned to perform urodynamic recordings in both
AOAB (30 rats) and COAB (30 rats) populations, divi-
ded into six subgroups (each including 10 rats),
according to the OAB model and studied compound
in the selected dose. Therefore, initially we decided
to enrol 10 rats serving as a control group, to enable
further comparison of urodynamic findings. The pre-
liminary results of the urodynamic study mentioned
above has already been published in 2011 [15].
AOAB – acute overactive bladder group
The AOAB model was evoked by a single i.p.
administration of cyclophosphamide (Sigma-Aldrich;
200 mg/kg body weight). According to the litera-
ture data [13, 14], 4-24 h after exposure an acute
HC is developed with bladder overactivity. The indi-
rect evidence demonstrating bladder inflammation
development was haematuria observed in some
studied subjects. The next day an ECG recording
was performed followed by a HRV analysis. Finally,
the rat was put down by pentobarbital (Morbital,
Biowet, Puławy) overdose. 
COAB – chronic overactive bladder group
The COAB model was caused by four times i.p.
CYP administration (Sigma-Aldrich; 75 mg/kg body
weight), every third day during 1 week (1st, 3rd, 5th
and 7th day). This results in chronic chemical blad-
der inflammation [13, 14]. We also observed pro-
gressive haematuria, which appeared in most COAB
subjects after the last CYP dose. On the 8th day, si-
milarly to the AOAB group, an ECG recording was
recorded and after these procedures the animal was
lethally anaesthetized. 
Control group
The studied animals received single (control to
AOAB) or four-times (control to COAB) saline i.p.
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injection in similar volumes as those administered
in AOAB/COAB. 
HRV studies
Under urethane anaesthesia (1200 mg/kg body
weight; Sigma-Aldrich) ECG recordings were per-
formed during 20-minute rest periods in each studied
animal. This anaesthetic agent was chosen having
taken into consideration the literature reports which
suggested the proportional (up to the applied dose)
impact on tonic activity of both sympathetic and
parasympathetic ANS parts and relatively small influ-
ence on cardiac reflexes [16, 17]. After terminating
ECG registration and extrasinusal ectopics elimina-
tion, HRV analysis was performed. Standard time
(mNN [ms], max and min NN [ms], SDNN [ms], aver-
age HR [bpm], rMSSD) and spectral (TP, VLF, LF, HF –
all in [ms*ms] and normalized nLF and nHF in [n.u.])
parameters were calculated. The frequency range for
respective spectral components was set as 0.18 < VLF
< 0.28 < LF < 0.78 < HF < 3 and commonly accepted
interpretation criteria were adopted: TP reflects glob-
al ANS activity, HF and nHF reflect parasympathetic
tension while nLF reflects a pure sympathetic one,
and LF is both a sympathetic and parasympathetic
measure. Results are presented as mean ± SD. 
Urinary bladder assessment
In both AOAB and COAB rats, urinary bladders
were red, swollen and in selected cases covered by
abundant serosal petechial suffusions. Leucocyte
infiltration of the bladder wall was demonstrated
in both OAB groups. Histological inflammatory
changes were more pronounced in COAB rats. The
control rats had normal bladders.
Statistical analysis
The statistical assessment of the results obtai-
ned was conveyed after expressing them as ln val-
ues using parametric test analysis of variations
(Bartlett’s test) with α = 0.05. The H0 hypothesis
of equality of analysed parameter variations in the
three studied populations was verified versus an
alternative hypothesis H1 of their inequality (thus,
the existence of statistically significant differences).
When hypothesis H1 for an individual parameter for
the three groups was accepted, the next statistical
step was to compare the differences between two
groups (control vs. AOAB, control vs. COAB, and AOAB
vs. COAB) using the parametric Fisher-Snedecor test
with the same α value.
Results
HRV analysis
Most of the obtained intergroup time HRV analy-
sis results were insignificant, except SDNN and
rMSSD. SDNN values were the highest in the con-
trol group (4.34 ±2.11) and were lower in both OAB
groups (3.24 ±2.08 in AOAB and 3.66 ±4.04 in COAB).
These differences were statistically significant 
(p < 0.05) when comparing all studied groups (1-3)
simultaneously and when analysing the control
group with AOAB and COAB separately. rMSSD
reached the highest value in the COAB group (2.36
±5.32), while in AOAB it was similar to the control
(1.65 ±2.77 and 1.56 ±0.82, respectively); rMSSD
changes were statistically significant when analy-
sing for all three studied populations and for com-
parison of the control group with COAB and the
AOAB group with COAB. 
When analysing the general trend observed in
other time-domain HRV parameters, it should be
emphasized that some of them (minNN and
rMSSD) were increased or decreased (SDNN) in
both OAB populations. The basic time domain
analysis parameter, mNN, was higher in the AOAB
group (171.05 ±12.0 ms) and diminished in the COAB
group (163.61 ±12.72 ms) when compared to the
control group (167.84 ±14.31 ms); non-significant.
The statistical estimation of calculated spectral
HRV analysis parameters indicates intergroup dif-
ferences related to all non-normalized power com-
ponents. Generally, the power spectrum of TP and
its components was lower in both groups with blad-
der overactivity (1.43 ±1.21 in AOAB and 2.15 ±2.17
in COAB compared to 7.92 ±6.22 in control; p < 0.05
for all groups). Compared to control, the AOAB
group was characterized mostly by pronounced TP
(see above) and VLF (0.95 ±1.08) decrease. In COAB,
both HF (0.25 ±0.29) and LF (0.09 ±0.15) reduction
was clearly expressed. Contrariwise, normalized
(nLF and nHF) spectral parameters obtained in all
studied populations showed similar values without
statistical significance. nLF was 33.76 ±19.50 n.u. in
control rats, 32.83 ±20.87 n.u. in AOAB and 27.54
±19.61 n.u. in COAB (p > 0.05) while nHF reached
66.25 ±19.50 n.u. in controls, 67.17 ±20.90 n.u. in
AOAB and 72.46 ±19.62 n.u. in COAB (p > 0.05). 
The results described above are presented in
Table I below.
Moreover, while analysing non-normalized spec-
tral analysis parameter results, the proportional par-
ticipation of power AOAB and COAB spectra related
to the control spectrum (whose power components
were treated as 100%) were calculated and pre-
sented in Figure 1 below. 
Discussion
As far as we know, our research is the first study
revealing autonomic nervous system disturbances
in an experimental, CYP-induced OAB model. In
brief, we found that the AOAB model was charac-
terized by a deep withdrawal of VLF and TP powers
(the fall in TP seems be a consequence of VLF
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decline because VLF mostly contributes to the TP
value). Moreover, relatively high (although lower
than in control) LF and HF percentages were not-
ed, probably reflecting the intensified inflammato-
ry bladder changes (Figure 1). In COAB, a power 
decrease of all spectral components was also
demonstrated, but contrary to AOAB, the dispro-
portions between particular components’ values
were not so marked in this group. Compared with
AOAB, we observed less TP and VLF reduction, but
LF and HF were more reduced (Figure 1).
The pathophysiological interpretation of the
obtained results, especially those in respect to VLF,
is difficult, taking into consideration that the me-
chanisms reflected in this spectral component are
poorly understood. There is a common agreement
that VLF is related to short-term sympathetic reg-
ulatory mechanisms relevant to chemoreceptors,
the renin-angiotensin-aldosterone system, ther-
moregulatory activity and other hard-to-define phe-
nomena [8, 9, 11]. Furthermore, there are studies
suggesting that global HRV and especially VLF
decrease is negatively correlated with intensification
of inflammatory changes and proinflammatory
cytokine levels [18, 19]. The VLF power value reduc-
tion is considered in cardiology to be an un -
favourable prognostic factor of cardiovascular com-
plications, arising from autonomic neuropathy [20].
Our work revealed a considerable VLF decrease in
AOAB subjects, which is compliant with the predic-
tive role of this spectral component in the inflam-
matory changes mentioned above. The relatively
high percentage of HF in the HRV spectrum may
reflect the increased compensatory reaction, con-
cerning the cholinergic anti-inflammatory pathway
[21]. In COAB, the chronic character of the inflam-
matory process develops a smaller hypercytoki-
Group Statistical analysis
Control (group 1) AOAB (group 2) COAB (group 3) Bartlett’s test Fisher-Snedecor test
Time domain analysis Groups Groups Groups Groups 
1-3 1-2 1-3 2-3
Mean NN [ms] 167.84 ±14.31 171.05 ±12.00 163.61 ±12.72 NS
SDNN 4.34 ±2.11 3.24 ±2.08 3.66 ±4.04 * * * NS
Max NN [ms] 180.49 ±12.23 178.65 ±10.96 173.10 ±14.25 NS
Min NN [ms] 153.85 ±12.71 162.27 ±12.22 156.08 ±13.41 NS
Mean HR [bpm] 359.94 ±31.69 352.54 ±25.15 368.71 ±27.87 NS
rMSSD 1.56 ±0.82 1.65 ±2.77 2.36 ±5.32 * NS * *
Spectral domain analysis
TP [ms2] 7.92 ±6.22 1.43 ±1.21 2.15 ±2.17 * * * *
VLF [ms2] 6.97 ±5.99 0.95 ±1.08 1.81 ±1.90 * * * *
LF [ms2] 0.34 ±0.33 0.16 ±0.33 0.09 ±0.15 * * * *
HF [ms2] 0.60 ±0.41 0.32 ±0.30 0.25 ±0.29 * * * NS
LF/HF 0.67 ±0.64 0.69 ±0.68 0.51 ±0.55 NS
nLF [n.u.] 33.76 ±19.50 32.83 ±20.87 27.54 ±19.61 NS
nHF [n.u.] 66.25 ±19.50 67.17 ±20.90 72.46 ±19.62 NS
Table I. Selected HRV time and frequency (spectral) domain analysis parameters 
[[%%
]]
TP                       VLF                      LF                       HF
Figure 1. Percentages of HRV spectral components
in OAB studied groups related to control group val-
ues treated as 100%
TP – total power of HRV spectrum, VLF – very low frequency
(component of HRV spectrum), LF – low frequency (compo-
nent of HRV spectrum), HF – high frequency (component of
HRV spectrum)
60
50
40
30
20
10
0
*Statistically significant, p < 0.05; NS – nonsignificant 
SDNN – standard deviation of all NN intervals, rMSSD – root mean square of standard deviation of all NN intervals, TP – total power of HRV
spectrum, VLF – very low frequency (component of HRV spectrum), LF – low frequency (component of HRV spectrum), HF – high frequency (com-
ponent of HRV spectrum), nLF – normalized LF value, nHF – normalized HF value
AOAB COAB
18.1
27.1
13.6
25.9
47.1
53.3
41.6
26.4
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naemia level and sympathetic-vagal imbalance
(expressed as VLF increase and HF decrease, com-
pared to AOAB). The interpretative difficulties
become more apparent when the results demon-
strating similar spectral normalized parameter val-
ues in both OAB and control groups are taken into
consideration. In our assessment, the lack of con-
siderable differences between normalized HRV
parameters paradoxically supports the hypothesis
regarding the specific character of autonomic dis-
turbances manifesting mostly in the VLF range
(which is intentionally omitted in the HRV spectrum
normalization process). Further experimental and
clinical investigations are needed to reveal the role
of HRV spectral abnormalities in bladder inflam-
mation and overactivity detection.
It must be emphasized that our results are con-
sistent with the general tendency found in the few
clinical studies in this research area. Choi et al. [22]
reported that female OAB patients were character-
ized by a drop in time domain parameters SDNN
and rMSSD and a notable reduction in TP, VLF and
HF powers. Our findings suggest, however, that LF
power is also decreased in an experimental OAB
model that may be secondary to parasympathetic
withdrawal and sympathetic augmentation during
bladder inflammatory damage evoked by CYP. Hu-
beaux et al. [23] performed a study estimating the
not-so-global AUN activity, as did Choi et al. [22],
but the ANS activity during the filling period was
evaluated in female patients with stress urinary
incontinence (SUI) and idiopathic OAB (IOAB). They
showed that the IOAB group was characterized by
a more intense resting parasympathetic activity
(demonstrated as HF power increase), while during
bladder filling progressive HF reduction with LF
increase was observed. Contrariwise, SUI subjects
were revealed to have more stable autonomic bal-
ance in both resting and filling periods. According
to Hubeaux et al. [23], in IOAB the proportions
between two main ANS branches change from
parasympathetic predominance in the storage pe-
riod to sympathetic advantage during pre-micturi-
tion that may reflect abnormal autonomic control
of bladder filling and emptying. Liao et al. [24] also
found that in IOAB patients the main time domain
parameter, mNN, is lower than in control subjects.
However, contrary to Choi et al. [22] they demon-
strated SDNN and rMSSD increase but confirmed
TP and VLF decrease in the IOAB group. Moreover,
apart from HRV estimation during resting, Liao et al.
[24] studied ANS variation in pre- and micturition
vs. postmicturition periods. Considering the first,
wider observation time they found that the control
group was characterized by VLF and LF powers au -
gmentation with small HF component representa-
tion. Recordings after bladder emptying suggested
further LF predominance with no VLF presence in
the HRV spectrum. In IOAB patients, considerable
HF increase with both LF and HF drops in the first
observation period were revealed, and these ten-
dencies were strengthened and deepened after
micturition.  
We cannot directly treat from these clinical fin-
dings due to the considerable methodological dif-
ferences (we studied only resting conditions, not
with reference to pre- and inter-micturition periods)
and mostly because of the fact that one cannot
simply compare the results obtained in clinical and
experimental conditions. However, estimating glo-
bal trends, our findings also support the hypothe-
sis of autonomic disturbances in OAB course, man-
ifesting as diminishing values of non-normalized
HRV spectral components.
In conclusion, both acute (AOAB) and chronic
(COAB) overactive experimental models seem to be
characterized by disturbed autonomic nervous sys-
tem activity manifested by diminished power spec-
tral components in both OAB groups. In the AOAB
group, VLF power withdrawal with relatively high
LF and HF values was especially pronounced, which
may suggest bladder inflammatory intensification.
On the other hand, the COAB group was characteri-
zed by lower disproportions in spectral component
powers; TP and VLF reached higher values while LF
and HF reached lower ones than in AOAB, although
all spectral components were, similarly to AOAB,
diminished when compared to the control. Normali-
zed frequency parameters nLF and nHF were simi-
lar in both AOAB and COAB; therefore it seems that
the differences of VLF power (as a component that
is not involved in spectrum normalization calcula-
tion) in OAB groups are of great importance. 
Re f e r e n c e s
 1. Abrams P, Cardozo L, Fall M, et al. The standardisation of
terminology of lower urinary tract function: report from
the Standardisation Sub-committee of the International
Continence Society. Neurourol Urodyn 2002; 21: 167-78.
 2. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Ker-
rebroeck P, Sand P. Reviewing the ICS 2002 terminology
report: the ongoing debate. Neurourol Urodyn 2006; 25: 293.
 3. Tubaro A, Palleschi G. Overactive bladder: epidemiology and
social impact. Curr Opin Obstet Gynecol 2005; 17: 507-11.
 4. Hashim H, Abrams P. Overactive bladder: an update. Curr
Opin Urol 2007; 17: 231-6.
 5. Chu FM, Dmochowski R. Pathophysiology of overactive
bladder. Am J Med 2006; 119 (3 Suppl 1): 3-8.
 6. Andersson KE, Pehrson R. CNS involvement in overactive
bladder: pathophysiology and opportunities for pharma-
cological intervention. Drugs 2003; 63: 2595-611.
 7. Zygmunt A, Stanczyk J. Methods of evaluation of autono-
mic nervous system function. Arch Med Sci 2010; 6: 11-8.
 8. Heart rate variability. Standards of measurement, physiolog-
ical interpretation, and clinical use. Task Force of the Euro-
pean Society of Cardiology and the North American Society
of Pacing and Electrophysiology. Eur Heart J 1996; 17: 354-81.
 9. Rajendra Acharya U, Paul Joseph K, Kannathal N, Lim CM,
Suri JS. Heart rate variability: a review. Med Biol Eng Com-
put 2006; 44: 1031-51.
Łukasz Dobrek, Piotr Thor 
Arch Med Sci 5, October / 2013 935
10. Kleiger RE, Stein PK, Bosner MS, Rottman JN. Time domain
measurements of heart rate variability. Cardiol Clin 1992;
10: 487-98.
11. Ori Z, Monir G, Weiss J, Sayhouni X, Singer DH. Heart rate
variability. Frequency domain analysis. Cardiol Clin 1992;
10: 499-537.
12. Cox PJ. Cyclophosphamide cystitis – identification of
acrolein as the causative agent. Biochem Pharmacol 1979;
28: 2045-9.
13. Dinis P, Charrua A, Avelino A, et al Anandamide-evoked
activation of vanilloid receptor 1 contributes to the devel-
opment of bladder hyperreflexia and nociceptive trans-
mission to spinal dorsal horn neurons in cystitis. J Neu-
rosci 2004; 24: 11253-63.
14. Chopra B, Barrick SR, Meyers S, et al. Expression and func-
tion of bradykinin B1 and B2 receptors in normal and
inflamed rat urinary bladder urothelium. J Physiol 2005;
562: 859-71.
15. Dobrek Ł, Thor PJ. The influence of melatonin and agome-
latine on urodynamic parameters in experimental over-
active bladder model: preliminary results. Postepy Hig
Med Dosw 2011; 65: 725-33.
16. Maggi CA, Meli A. Suitability of urethane anesthesia for
physiopharmacological investigations in various systems.
Part 1: General considerations. Experientia 1986; 42: 109-14.
17. Maggi CA, Meli A. Suitability of urethane anesthesia for
physiopharmacological investigations in various systems.
Part 2: cardiovascular system. Experientia 1986; 42: 292-7.
18. Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE.
The relationship between heart rate variability and inflam-
matory markers in cardiovascular diseases. Psychoneu-
roendocrinology 2008; 33: 1305-12.
19. Lampert R, Bremner JD, Su S, et al. Decreased heart rate
variability is associated with higher levels of inflamma-
tion in middle-aged men. Am Heart J 2008; 156: 759.e1-7.
20. Hadase M, Azuma A, Zen K, et al. Very low frequency pow-
er of heart rate variability is a powerful predictor of clinical
prognosis in patients with congestive heart failure. Circ J
2004; 68: 343-7.
21. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve sti-
mulation attenuates the systemic inflammatory response
to endotoxin. Nature 2000; 405: 458-62.
22. Choi JB, Kim YB, Kim BT, Kim YS. Analysis of heart rate va-
riability in female patients with overactive bladder. Urol-
ogy 2005; 65: 1109-12.
23. Hubeaux K, Deffieux X, Ismael SS, Raibaut P, Amarenco
G. Autonomic nervous system activity during bladder fill-
ing assessed by heart rate variability analysis in women
with idiopathic overactive bladder syndrome or stress uri-
nary incontinence. J Urol 2007; 178: 2483-7.
24. Liao WC, Jaw FS. A noninvasive evaluation of autonomic
nervous system dysfunction in women with an overac-
tive bladder. Int J Gynaecol Obstet 2010; 110: 12-7.
Heart rate variability in overactive bladder experimental model
